1
|
Jiang Z, You Q, Zhang X. Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective. Eur J Med Chem 2019; 165:172-197. [PMID: 30684796 DOI: 10.1016/j.ejmech.2019.01.018] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2018] [Revised: 12/22/2018] [Accepted: 01/08/2019] [Indexed: 12/25/2022]
Abstract
Numerous metal-containing enzymes (metalloenzymes) have been considered as drug targets related to diseases such as cancers, diabetes, anemia, AIDS, malaria, bacterial infection, fibrosis, and neurodegenerative diseases. Inhibitors of the metalloenzymes have been developed independently, most of which are mimics of substrates of the corresponding enzymes. However, little attention has been paid to the interactions between inhibitors and active site metal ions. This review is focused on different metal binding fragments and their chelating properties in the metal-containing active binding pockets of metalloenzymes. We have enumerated over one hundred of inhibitors targeting various metalloenzymes and identified over ten kinds of fragments with different binding patterns. Furthermore, we have investigated the inhibitors that are undergoing clinical evaluation in order to help looking for more potential scaffolds bearing metal binding fragments. This review will provide deep insights for the rational design of novel inhibitors targeting the metal-containing binding sites of specific proteins.
Collapse
Affiliation(s)
- Zhensheng Jiang
- Sate Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Qidong You
- Sate Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
| | - Xiaojin Zhang
- Sate Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China; Department of Chemistry, School of Science, China Pharmaceutical University, Nanjing, 211198, China.
| |
Collapse
|
2
|
Xie XW, Wan RZ, Liu ZP. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents. ChemMedChem 2017; 12:1157-1168. [DOI: 10.1002/cmdc.201700349] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2017] [Revised: 07/04/2017] [Indexed: 01/07/2023]
Affiliation(s)
- Xin-Wen Xie
- Institute of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences; Shandong University; Jinan 250012 P.R. China
| | - Ren-Zhong Wan
- College of Animal Science & Veterinary Medicine; Shandong Agricultural University; 61 Daizong Street Taian 271018 P.R. China
| | - Zhao-Peng Liu
- Institute of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences; Shandong University; Jinan 250012 P.R. China
| |
Collapse
|
3
|
Gerfaud T, Martin C, Bouquet K, Talano S, Millois-Barbuis C, Musicki B, Boiteau JG, Cardinaud I. Process Development and Good Manufacturing Practice Production of a Tyrosinase Inhibitor via Titanium-Mediated Coupling between Unprotected Resorcinols and Ketones. Org Process Res Dev 2017. [DOI: 10.1021/acs.oprd.7b00036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Thibaud Gerfaud
- Nestlé Skin Health R&D, 2400 Route des colles BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Cédric Martin
- Nestlé Skin Health R&D, 2400 Route des colles BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Karinne Bouquet
- Nestlé Skin Health R&D, 2400 Route des colles BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Sandrine Talano
- Nestlé Skin Health R&D, 2400 Route des colles BP 87, 06902 Sophia-Antipolis Cedex, France
| | | | - Branislav Musicki
- Nestlé Skin Health R&D, 2400 Route des colles BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Jean-Guy Boiteau
- Nestlé Skin Health R&D, 2400 Route des colles BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Isabelle Cardinaud
- Nestlé Skin Health R&D, 2400 Route des colles BP 87, 06902 Sophia-Antipolis Cedex, France
| |
Collapse
|
4
|
Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays. Bioorg Med Chem 2016; 24:4291-4309. [DOI: 10.1016/j.bmc.2016.07.023] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Revised: 07/11/2016] [Accepted: 07/12/2016] [Indexed: 12/28/2022]
|
5
|
Zapico JM, Puckowska A, Filipiak K, Coderch C, de Pascual-Teresa B, Ramos A. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family. Org Biomol Chem 2015; 13:142-56. [DOI: 10.1039/c4ob01516a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Triazole-based inhibitors with high potency and selectivity for MMP-2 were obtained through a click chemistry approach.
Collapse
Affiliation(s)
- José María Zapico
- Departamento de Química y Bioquímica
- Facultad de Farmacia
- Universidad CEU San Pablo
- 28668 Madrid
- Spain
| | - Anna Puckowska
- Departamento de Química y Bioquímica
- Facultad de Farmacia
- Universidad CEU San Pablo
- 28668 Madrid
- Spain
| | - Kamila Filipiak
- Departamento de Química y Bioquímica
- Facultad de Farmacia
- Universidad CEU San Pablo
- 28668 Madrid
- Spain
| | - Claire Coderch
- Departamento de Química y Bioquímica
- Facultad de Farmacia
- Universidad CEU San Pablo
- 28668 Madrid
- Spain
| | | | - Ana Ramos
- Departamento de Química y Bioquímica
- Facultad de Farmacia
- Universidad CEU San Pablo
- 28668 Madrid
- Spain
| |
Collapse
|
6
|
Li NG, Tang YP, Duan JA, Shi ZH. Matrix metalloproteinase inhibitors: a patent review (2011 – 2013). Expert Opin Ther Pat 2014; 24:1039-52. [DOI: 10.1517/13543776.2014.937424] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
7
|
Fabre B, Filipiak K, Díaz N, Zapico JM, Suárez D, Ramos A, de Pascual-Teresa B. An Integrated Computational and Experimental Approach to Gaining Selectivity for MMP-2 within the Gelatinase Subfamily. Chembiochem 2014; 15:399-412. [DOI: 10.1002/cbic.201300698] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Indexed: 12/27/2022]
|
8
|
Fabre B, Filipiak K, Zapico JM, Díaz N, Carbajo RJ, Schott AK, Martínez-Alcázar MP, Suárez D, Pineda-Lucena A, Ramos A, de Pascual-Teresa B. Progress towards water-soluble triazole-based selective MMP-2 inhibitors. Org Biomol Chem 2013; 11:6623-41. [DOI: 10.1039/c3ob41046c] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
9
|
Hydroxamic Acids as Matrix Metalloproteinase Inhibitors. MATRIX METALLOPROTEINASE INHIBITORS 2012; 103:137-76. [DOI: 10.1007/978-3-0348-0364-9_5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
|
10
|
MMP-13 selective α-sulfone hydroxamates: A survey of P1′ heterocyclic amide isosteres. Bioorg Med Chem Lett 2011; 21:2820-2. [DOI: 10.1016/j.bmcl.2011.03.099] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2011] [Revised: 03/23/2011] [Accepted: 03/24/2011] [Indexed: 11/22/2022]
|
11
|
Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP. MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1′ amides. Bioorg Med Chem Lett 2011; 21:2823-5. [DOI: 10.1016/j.bmcl.2011.03.095] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2011] [Revised: 03/23/2011] [Accepted: 03/24/2011] [Indexed: 10/18/2022]
|
12
|
Zhang H, Chang M, Hansen CN, Basso DM, Noble-Haeusslein LJ. Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 2011; 8:206-20. [PMID: 21455784 PMCID: PMC3077748 DOI: 10.1007/s13311-011-0038-0] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
This review will focus on matrix metalloproteinases (MMPs) and their inhibitors in the context of spinal cord injury (SCI). MMPs have a specific cellular and temporal pattern of expression in the injured spinal cord. Here we consider their diverse functions in the acutely injured cord and during wound healing. Excessive activity of MMPs, and in particular gelatinase B (MMP-9), in the acutely injured cord contributes to disruption of the blood-spinal cord barrier, and the influx of leukocytes into the injured cord, as well as apoptosis. MMP-9 and MMP-2 regulate inflammation and neuropathic pain after peripheral nerve injury and may contribute to SCI-induced pain. Early pharmacologic inhibition of MMPs or the gelatinases (MMP-2 and MMP-9) results in an improvement in long-term neurological recovery and is associated with reduced glial scarring and neuropathic pain. During wound healing, gelatinase A (MMP-2) plays a critical role in limiting the formation of an inhibitory glial scar, and mice that are genetically deficient in this protease showed impaired recovery. Together, these findings illustrate complex, temporally distinct roles of MMPs in SCIs. As early gelatinase activity is detrimental, there is an emerging interest in developing gelatinase-targeted therapeutics that would be specifically tailored to the acute injured spinal cord. Thus, we focus this review on the development of selective gelatinase inhibitors.
Collapse
Affiliation(s)
- Haoqian Zhang
- Department of Neurosurgery, University of California, San Francisco, California 94143-0110, USA.
| | | | | | | | | |
Collapse
|
13
|
Zapico JM, Serra P, García-Sanmartín J, Filipiak K, Carbajo RJ, Schott AK, Pineda-Lucena A, Martínez A, Martín-Santamaría S, de Pascual-Teresa B, Ramos A. Potent “Clicked” MMP2 Inhibitors: Synthesis, Molecular Modeling and Biological Exploration. Org Biomol Chem 2011; 9:4587-99. [DOI: 10.1039/c0ob00852d] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. J Med Chem 2010; 53:6653-80. [PMID: 20726512 DOI: 10.1021/jm100669j] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent inhibitors of MMP's-2, -9, and -13 that spare MMP-1, with oral efficacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine cartilage degradation ex vivo explant system. α-Piperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i (SC-77774), respectively, were identified as backup compounds.
Collapse
Affiliation(s)
- Daniel P Becker
- Pfizer Research, 700 Chesterfield Village Parkway, St. Louis, Missouri 63198, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Kolodziej SA, Hockerman SL, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Stehle N, Swearingen C, Becker DP. MMP-13 selective isonipecotamide α-sulfone hydroxamates. Bioorg Med Chem Lett 2010; 20:3561-4. [DOI: 10.1016/j.bmcl.2010.04.111] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2010] [Revised: 04/23/2010] [Accepted: 04/26/2010] [Indexed: 11/24/2022]
|